Document Detail


Single agent versus combination chemotherapy in recurrent cervical cancer.
MedLine Citation:
PMID:  10063235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Cisplatin and ifosfamide are two most active agents in patients with recurrent and metastatic cervical cancer. Combination of bleomycin, ifosfamide and cisplatinum (BIP) was compared with cisplatinum alone. PATIENTS AND METHODS: One hundred and six patients with recurrent/persistent and metastatic cervical cancer received either a combination of bleomycin, ifosfamide and cisplatinum, (Group A, n = 50) or cisplatinum alone (Group B, n = 56) every 3 weeks for up to 6 courses. Ninety-seven patients were evaluable and were analysed for response and survival. RESULTS: Patients receiving BIP (Group A) had a higher response rate (complete and partial responses), 52.2% vs 29.4%, p < 0.01 with overall median survival, 8 months (1 to 92+ months) vs 6 months (1 to 40+ months), p = 0.18. Chemotherapy responders had a significantly higher survival in both groups compared to the non-responders (Group A: 17 vs 6 months, p < 0.001, Group B: 20.5 months vs 5 months, p < 0.001). Patients in good performance status (ECOG, 0-2) had a significantly higher response rate to chemotherapy (Group A: 70.3% vs 26.3%, p < 0.01, Group B: 38.2% vs 11.7%, p < 0.05). In Group A, patients with extrapelvic disease responded better compared to pelvic disease (83.3% vs 34.5%, p < 0.01). Chemotherapy side effects were mainly nausea/vomiting, alopecia, myelosuppression, reversible encephalopathy (in Group A), and impaired renal functions. Chemotherapy toxicity was higher for patients receiving BIP, 2 patients died of BIP toxicity. Currently, in 'Group A' 8 patients are alive, 7 disease-free and one with disease at a median interval of 51 months after chemotherapy treatment. While in Group B, 3 patients are alive, 2 disease-free and one with disease. CONCLUSIONS: Bleomycin, ifosfamide and cisplatin improved the response rate in recurrent and metastatic cervical cancer compared with cisplatinum alone. However, the toxicity was moderate and survival was not significantly improved. These results need to be confirmed in a phase III, randomized study in larger number of patients.
Authors:
L Kumar; Y H Pokharel; S Kumar; R Singh; G K Rath; V Kochupillai
Related Documents :
3114435 - Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatmen...
2112055 - Experience of the belgian society of medical oncology with single-administration 5 g/m2...
3169095 - Ifosfamide in previously untreated disseminated neuroblastoma. results of study 3a of t...
1608355 - Phase ii trial of ifosfamide/mesna and mitoxantrone in previously treated patients with...
2715655 - Cutaneous melanoma in japan and the united states: comparative prognostic factors.
17923825 - Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The journal of obstetrics and gynaecology research     Volume:  24     ISSN:  1341-8076     ISO Abbreviation:  J. Obstet. Gynaecol. Res.     Publication Date:  1998 Dec 
Date Detail:
Created Date:  1999-03-18     Completed Date:  1999-03-18     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9612761     Medline TA:  J Obstet Gynaecol Res     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  401-9     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / administration & dosage
Cisplatin / administration & dosage
Female
Humans
Ifosfamide / administration & dosage
Middle Aged
Neoplasm Recurrence, Local / drug therapy*,  mortality
Survival Analysis
Uterine Cervical Neoplasms / drug therapy*,  mortality,  secondary
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 11056-06-7/Bleomycin; 15663-27-1/Cisplatin; 3778-73-2/Ifosfamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fertility outcome after reversal of sterilization.
Next Document:  Evaluation of insulin-like growth factor binding protein-1 as a diagnostic tool for rupture of the m...